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BRS-3 is an orphan G protein coupled receptor highly expressed in the brain. Pharmacological studies in this
issue (Guan et al., 2010) further support a role for this receptor in energy homeostasis and show that the BRS-
3 agonist Bag-1 effectively causes weight loss by decreasing food intake and increasing metabolic rate.The primacy of the central nervous
system in controlling energy consumption
and storage is clear. A wealth of data from
human genetic and rodent studies con-
tinues to reiterate that, when it comes to
the key influences of appetite and satiety,
the brain is where it’s at (O’Rahilly and
Farooqi, 2008). Modulation of these cen-
tral pathways, therefore, forms the poten-
tial basis for rational therapies for disor-
ders of energy homeostasis, including
obesity. An ideal drug would be taken
orally before entering specific regions of
the brain in sufficient concentration to
bring about the desired changes in food
intake and body weight, without upsetting
too many other systems along the way.
As a result, pathways based around
melanocortins, serotonin, dopamine, and
endocannabinoids have all garnered
extensive pharmacological attention in
recent years. In addition to these princi-
pals, however, other players have a part
in the orchestrated ensemble necessary
to regulate energy homeostasis. In this
issue of Cell Metabolism, work by Reit-
man and colleagues (Guan et al., 2010)
allows the bombesin receptor subtype 3
(BRS-3) to step back into the limelight.
The bombesin receptor family is made
up of three G protein coupled receptors:
neuromedin B receptor (NMB-R), gastrin-
releasing peptide receptor (GRP-R), and
BRS-3 (Jensen et al., 2008). NMB-R and
GRP-R are widely expressed throughout
the body, particularly in the gastrointes-
tinal (GI) tract and the CNS, and are the
most well-characterized members of the
family. The endogenous peptide ligands
NMB and GRP signal via their cognate
receptors to regulate a diverse range of
physiological functions, including GI
motility, hormone release and secretion,
thermoregulation, tissue growth, and
circadian rhythm (Jensen et al., 2008).The biology of BRS-3 has been, to date,
less well defined. Both NMB and GRP
have low affinity for this receptor, and its
endogenous ligand remains unknown.
Strong evidence that BRS-3 has a role in
metabolism first came in 1997 with the
report of a knockout mouse globally lack-
ing the receptor (Ohki-Hamazaki et al.,
1997). BRS-3 deficient mice become
overweight at 16 weeks, a result of in-
creased food intake and a reduced meta-
bolic rate (Ladenheim et al., 2008). They
also have an enhanced hyperphagic
response to the orexigen melanin-con-
centrating hormone, potentially due to up-
regulation of MCH receptor expression
(Maekawa et al., 2004). The authors of
the initial knockout report presciently
commented that identification of a ligand
for this receptor would lead to the devel-
opment of therapies for obesity. In the
intervening years a number of molecules
targeting BRS-3 have been reported, but
many were hampered by lack of potency
and selectivity.
So, have Guan and colleagues cracked
it? The agonist used in the study, the non-
peptide ligand Bag-1, is highly selective
for BRS-3 and has a favorable kinetic
profile that allows for oral administration.
At doses of 100 mg/kg, acute administra-
tion of Bag-1 can decrease food intake
and increase metabolic rate, the latter
persisting even when the mice were
fasted. Further, twice daily treatment for
8 days to diet-induced obese mice
reduced their food intake by 23% and
body weight by 11%. The authors go on
to utilize a second BRS-3 agonist radioli-
gand [3H] Bag-2 to not only show that
orally dosed BRS-3 ligand achieves high
receptor occupancy (80%) within the
hypothalamus postadministration, but
also to map out the distribution of BR3-3
within the brain. BRS-3 was found to beCell Metabolism 1abundant in the hypothalamus, particu-
larly within nuclei known to have key roles
in appetitive behavior, but was also de-
tected within dopaminergic and seroto-
nergic neurons. They also used multiple
mouse models to show that the anorexi-
genic effects of Bag-1 were independent
of the leptin-melanocortin and cannabi-
noid system. Finally, all of this appears
to happen without too much in the way
of untoward side effects, at least when
judged by behavior in an elevated plus
maze.
So far, so good. Yet, some important
issues remain to be addressed. Although
the drug’s efficacy appears reasonably
robust in these rodent models, the
neuronal circuits through which the
BRS-3 system acts remain unclear (Fig-
ure 1). The authors suggest that Bag-1
upregulates inhibitory postsynaptic
currents (IPSCs) in the hypothalamic
arcuate nucleus via a presynaptic mecha-
nism, but these analyses were done on
unidentified whole cells. Further, both
the electrophysiological studies and the
radiolabeled Bag-2 experiments concen-
trated on the arcuate; further data
concentrating on other regions known to
express BRS-3, such as the ventral
tegmental area (VTA) and the nucleus
tractus solitarius (NTS), would have been
informative. Indeed, a mechanism outside
of the CNS remains a possibility. BRS-3
immunoreactivity has been found
throughout the GI tract in rats (Jensen
et al., 2008), and the anorexigenic effects
of Bag-1 may conceivably, in part, be
driven by actions on the gut.
Worries about site of action are more
than rarified points of interest. If BRS-3
ligands are to make the leap into the clin-
ical arena, those conducting such studies
will need to remain acutely aware of the
potential for adverse side effects to sink1, February 3, 2010 ª2010 Elsevier Inc. 95
hypothalamus
VTA NTS
reduced food intake
+
Bag-1
BRS-3
?
?
?
?
increased metabolic rate
Figure 1. Activation of BRS-3 Causes Weight Loss
Bag-1 is a potent agonist at BRS-3, a receptor highly expressed within the
CNS. The pathways responsible for the anorexigenic effects of this ligand
remain to be fully elucidated but may involve multiple regions of the brain as
well as the gut.
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of rimonabant (an antagonist
at the cannabinoid 1 receptor)
due to psychiatric side effects
remains a bitter example of
how tricky it is to avoid
unwanted off-target actions
(Taylor, 2009). It also is a
reminder of how pathways
controlling energy balance
have become increasingly in-
tertwined with those previ-
ously thought to be solely
the province of psychologists
and behavioralists. As the
authors highlight, the fact
that Brs3 null mice have
already been reported to
have a penchant for palatable
oral stimuli (Yamada et al.,
1999) and to be less prone
to the adverse effects of
social isolation (Yamada
et al., 2000) indicates that
BRS-3 may have a biological
role that spills over into the
more emotive aspects of
food consumption.
One final aspect of this
receptor’s biology merits
discussion. Increased BRS-3expression has been reported in a range
of malignancies—in particular, cancers
arising from the lung—with activation of
the receptor being a potential promoter
of adhesion and metastasis (Hou et al.,
2006). With obesity already linked to an
increased incidence of malignancies,
any study involving chronic administration
to human subjects will require careful96 Cell Metabolism 11, February 3, 2010 ª2010 Elsevier Inc.selection and a high degree of clinical vigi-
lance throughout.
For now, however, Guan and
colleagues are to be congratulated for
bringing to the metabolic community
a collection of highly useful ligands that
have both the utility to mine further the
biological intricacies of an important
receptor and the potential to usher ina much-needed weight loss
drug. As the new decade
unfolds, we await develop-
ments with much interest.
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